Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Name | Pct Held | Shares | Total |
---|---|---|---|
Vanguard Extended Market Index Fund | 0.99% | 87.14k | 418.26k |
Vanguard Total Stock Market Index Fund | 0.86% | 75.95k | 364.56k |
Fidelity Extended Market Index Fund | 0.43% | 37.57k | 180.33k |
iShares Core S&P Total U.S. Stock Market ETF | 0.12% | 10.6k | 50.87k |
Fidelity Total Market Index Fund | 0.10% | 8.95k | 42.96k |
Vanguard Institutional Index-Inst Total Stock Market Ind | 0.06% | 5.69k | 27.31k |
Fidelity Series Total Market Index Fund | 0.06% | 5.6k | 26.9k |
Vanguard Balanced Index Fund | 0.06% | 5.5k | 26.38k |
Fidelity NASDAQ Composite Index Fund | 0.03% | 2.34k | 11.24k |
USAA Mutual Fd Tr-Extended Market Index Fd | 0.01% | 645 | 3.1k |
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
11/26 12:00 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
05/15 04:15 pm
GlobeNewswire Inc.
Read morePrincipal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
04/08 07:00 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports Year-End 2023 Corporate and Financial Results
03/25 05:45 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
03/22 12:30 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
01/22 08:30 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
01/08 09:24 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
12/21 12:00 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
11/09 06:00 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
09/11 07:00 am
GlobeNewswire Inc.
Read moreMarker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08/30 08:00 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
08/14 04:30 pm
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
08/07 07:00 am
GlobeNewswire Inc.
Read moreEuropean Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
07/10 07:00 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
06/26 07:00 am
GlobeNewswire Inc.
Read moreNasdaq Gains 1%; US Budget Deficit Widens In May
06/12 02:54 pm
Benzinga
Read moreMarker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
06/12 07:00 am
GlobeNewswire Inc.
Read moreUtilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
06/01 06:00 am
PennyStocks
Read moreNasdaq Down 100 Points; Advance Auto Parts Earnings Miss Views
05/31 12:06 pm
Benzinga
Read moreMarker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
05/31 06:30 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
05/08 07:30 am
GlobeNewswire Inc.
Read more7 Low Float Penny Stocks To Watch After SNTG Stock Explodes
05/01 12:10 pm
PennyStocks
Read moreMarker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™
05/01 07:30 am
GlobeNewswire Inc.
Read moreMarker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
03/22 08:10 am
GlobeNewswire Inc.
Read moreMarker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
12/13 08:00 am
GlobeNewswire Inc.
Read moreMARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
11/10 06:35 pm
Zacks Investment Research
Read more3 Hot Penny Stocks To Buy For Under $1 Right Now
10/14 12:53 pm
PennyStocks
Read moreMarker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
09/13 07:00 am
GlobeNewswire Inc.
Read moreWhy ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
09/09 04:13 am
Benzinga
Read moreMarker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference
09/08 07:00 am
GlobeNewswire Inc.
Read moreWhy AMC Entertainment Is Trading Lower By 33%; Here Are 31 Stocks Moving Premarket
08/22 07:13 am
Benzinga
Read moreMarker Therapeutics Reports Q2 2022 Operating and Financial Results
08/11 04:22 pm
GlobeNewswire Inc.
Read more